Page 0004

NEWS

As reported by Reuters, tiny Israeli

drugmaker Oramed Pharmaceuticals Inc,

has said that its experimental oral insulin

succeeded in significantly reducing nighttime blood glucose in patients with Type

2 diabetes, according to initial data from

a midstage trial.

The result is likely to surprise many

sceptics who did not believe insulin could

be delivered orally because they doubted

it could survive the onslaught of digestive

juices so it could have the intended effect.

Oramed uses a protective coating and a

high-enough dose of insulin so that most

of it can be destroyed and still deliver a

clinically beneficial amount

The positive results must be replicated

in a larger Phase III trial before the drug,

known as ORMD-0801, can be submitted

for approval. But the data from the

Phase II, 180-patient trial represents a

SIBLINGS NEEDED FOR STUDY

The adAPT Trial is a family study looking at the possibility of preventing

the onset of Type 1 diabetes through an inexpensive drug treatment

regime. The researchers are looking to recruit brothers and sisters

aged between 5 and 16 years old with a sibling who developed Type

1 diabetes when they were under the age of 25. They would also

like to involve the offspring aged between 5 and 16 years of a parent

who developed Type 1 diabetes when they were under the age of 25.

The trial is launching in Scotland with a second site due to be started

shortly in Newcastle. www.adaptdiabetes.org

ORAL INSULIN STILL POSSIBLE

major milestone. While insulin is typically

associated with Type 1 diabetes, many

patients with Type 2 eventually see their

disease progress to the point where they

need insulin. Type 2 accounts for more

than 90% of the nearly 400 million people

with diabetes worldwide.

A safe and effective oral insulin, if

approved, is expected to become a

multibillion-dollar product. The main

attraction of an insulin pill, aside from

avoiding injections, is that it comes much

closer to the path of natural insulin, which

is produced in the pancreas and goes

directly to the liver. ORMD-0801 goes

from the gut to the liver, while injected

insulin circulates throughout the body

before it gets there.

Image shows Oramed MD Nadav

Kidron holding the experimental pill.

As written by Jacinta Bowler for Science

Alert: "Type 1 diabetes isn't an easy

disease to put an end to; not only do

scientists have to fix the complete lack

of insulin being produced by the patient's

own pancreas, but the cells they try to

send in to help keep getting destroyed

by the immune system. It's a medical

catch-22. But a US patent has just been

approved for what could be the first

functional cure for the condition - by

combining insulin-delivering cells with

technology that allows them to hide from

the immune system for years at a time.

The cells are called 'Melligen cells', and

they can produce, store and release

insulin in response to blood sugar levels.

"University of Technology Sydney

(UTS) scientists have been genetically

engineering these Melligen cells for years

so they can release insulin in order to

regulate human blood sugar levels - just

like the beta cells that are destroyed by

type 1 diabetes are supposed to.

'"If we are successful in this effort,

it will bring to fruition the many years of

research that have been conducted by

Professor Simpson and her colleagues

at UTS in developing these remarkable

cells," said PharmaCyte's CEO Kenneth

Waggoner. "For the millions of people

worldwide who suffer from a disease

of epidemic proportions, our treatment

could relieve them of the onerous daily

requirements for insulin administration and

dietary restrictions and offer a life free from

the very serious and even life-threatening

complications associated with diabetes."

http://bit.ly/melligen_cells

PATENT FOR

POSSIBLE

TYPE 1 CURE

Index

  1. Desang diabetes magazine diabetes information
  2. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  3. Desang diabetes magazine diabetes information
  4. Page 0004
  5. Accu-Chek Mobile blood glucose system, Medical Detection Dogs, Limited Edition Accu-Chek Mobile pink
  6. Desang diabetes magazine diabetes news, Type 1 diabetes, Type 2 diabetes
  7. adAPT diabetes trial, Hid-In insulin pump belt
  8. Ascensia Contour Diabetes blood test meters
  9. Leatherice diabetes ID jewellery
  10. Desang diabetes magazine diabetes diet
  11. diabetic diet
  12. SugarBEAT
  13. Ascencia Contour Diabetes blood test meters
  14. Digital eye ID, Digital eye ID, Bausch+Lomb
  15. Digital eye ID, Bausch+Lomb
  16. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  17. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  18. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  19. Desang diabetes kitbags
  20. insulin pump wear AnnaPS, diabetesia Sofia Larsson-Stern
  21. insulin pump wear AnnaPS, diabetesia Sofia Larsson-Stern
  22. Making Carbs count: Counting carbs for the diabetic diet
  23. Making Carbs count: Counting carbs for the diabetic diet, the carb content of citrus fruit
  24. Making Carbs count: Counting carbs for the diabetic diet, the carb content of citrus fruit
  25. Accu-Chek Insight insulin pump
  26. Free diabetes magazine, Desang diabetes magazine

Related Issues